These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 32228512)

  • 1. Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study.
    Yalcin S; Dane F; Oksuzoglu B; Ozdemir NY; Isikdogan A; Ozkan M; Demirag GG; Coskun HS; Karabulut B; Evrensel T; Ustaoglu MA; Ozdemir F; Turna H; Yavuzsen T; Aykan F; Sevinc A; Akbulut H; Yuce D; Hayran M; Kilickap S
    BMC Cancer; 2020 Mar; 20(1):259. PubMed ID: 32228512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
    Von Hoff DD; Ervin T; Arena FP; Chiorean EG; Infante J; Moore M; Seay T; Tjulandin SA; Ma WW; Saleh MN; Harris M; Reni M; Dowden S; Laheru D; Bahary N; Ramanathan RK; Tabernero J; Hidalgo M; Goldstein D; Van Cutsem E; Wei X; Iglesias J; Renschler MF
    N Engl J Med; 2013 Oct; 369(18):1691-703. PubMed ID: 24131140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
    Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study.
    Zong Y; Yuan J; Peng Z; Lu M; Wang X; Shen L; Zhou J
    J Cancer Res Clin Oncol; 2021 May; 147(5):1529-1536. PubMed ID: 33191450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study.
    Feliu J; Jorge Fernández M; Macarulla T; Massuti B; Albero A; González González JF; Quintero-Aldana G; Delgado-Mingorance JI; Fernández Montes A; García Piernavieja C; Valladares-Ayerbes M; López Muñoz AM; Mondéjar Solís R; Vicente P; Casado Gonzalez E; González Cebrián I; López-Vivanco G
    Cancer Chemother Pharmacol; 2021 Apr; 87(4):543-553. PubMed ID: 33452559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice.
    De Vita F; Ventriglia J; Febbraro A; Laterza MM; Fabozzi A; Savastano B; Petrillo A; Diana A; Giordano G; Troiani T; Conzo G; Galizia G; Ciardiello F; Orditura M
    BMC Cancer; 2016 Sep; 16(1):709. PubMed ID: 27590845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
    Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.
    Ramanathan RK; Goldstein D; Korn RL; Arena F; Moore M; Siena S; Teixeira L; Tabernero J; Van Laethem JL; Liu H; McGovern D; Lu B; Von Hoff DD
    Ann Oncol; 2016 Apr; 27(4):648-53. PubMed ID: 26802153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry.
    Al-Batran SE; Hofheinz RD; Reichart A; Pauligk C; Schönherr C; Schlag R; Siegler G; Dörfel S; Koenigsmann M; Zahn MO; Schubert J; Aldaoud A; Höffkes HG; Schulz H; Hahn L; Uhlig J; Blau W; Stauch M; Weniger J; Wolf M; Jacobasch L; Bildat S; Wehmeyer J; Homann N; Trojan J; Waidmann O; Fietz T; Feustel HP; Groschek M; Wierecky J; Waibel K; Mahlmann S; Schwindel U; Peters U; Schuch G; Pink D; Eschenburg H; Wörns MA; Harich HD; von Weikersthal LF; Däßler KU; Behringer DM; Messmann H; Kretzschmar A; Gallmeier E; Forstbauer H; Kunzmann V; Papke J; Büchner-Steudel P; Vehling-Kaiser U; Springfeld C; Vogel A; Ettrich TJ; Schaaf M; Hausen GZ; Götze TO;
    Int J Cancer; 2021 Mar; 148(6):1478-1488. PubMed ID: 33038277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicenter, randomized, phase II study.
    Jin M; Liu HL; Xue J; Ma H; Liu JL; Lin ZY; Wang J; Bao LQ; Luo ZG; Yu XJ; Li S; Hu JL; Zhang T
    Oncologist; 2024 Oct; 29(10):e1406-e1418. PubMed ID: 38990195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).
    Rinaldi Y; Pointet AL; Khemissa Akouz F; Le Malicot K; Wahiba B; Louafi S; Gratet A; Miglianico L; Laharie H; Bouhier Leporrier K; Thirot Bidault A; Texereau P; Coriat R; Terrebonne E; Gouttebel MC; Malka D; Bachet JB; Lepage C; Taieb J;
    Eur J Cancer; 2020 Sep; 136():25-34. PubMed ID: 32623182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer.
    Borazanci E; Von Hoff DD
    Expert Rev Gastroenterol Hepatol; 2014 Sep; 8(7):739-47. PubMed ID: 24882381
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Korn RL; Von Hoff DD; Borad MJ; Renschler MF; McGovern D; Curtis Bay R; Ramanathan RK
    Cancer Imaging; 2017 Aug; 17(1):23. PubMed ID: 28774338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment.
    Petrillo A; Pappalardo A; Pompella L; Tirino G; Calabrese F; Laterza MM; Caterino M; Ventriglia A; Orditura M; Conzo G; Molino C; Ciardiello F; Biglietto M; De Vita F
    Med Oncol; 2019 Aug; 36(10):83. PubMed ID: 31444639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial.
    Cascinu S; Berardi R; Bianco R; Bilancia D; Zaniboni A; Ferrari D; Mosconi S; Spallanzani A; Cavanna L; Leo S; Negri F; Beretta GD; Sobrero A; Banzi M; Morabito A; Bittoni A; Marciano R; Ferrara D; Noventa S; Piccirillo MC; Labianca R; Mosconi C; Casadei Gardini A; Gallo C; Perrone F
    Eur J Cancer; 2021 May; 148():422-429. PubMed ID: 33812334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. nab-Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial.
    Young R; Mainwaring P; Clingan P; Parnis FX; Asghari G; Beale P; Aly A; Botteman M; Romano A; Ferrara S; Margunato-Debay S; Harris M
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e325-e331. PubMed ID: 29932294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarcinoma patients: the VESPA trial study protocol.
    Budillon A; Leone A; Passaro E; Silvestro L; Foschini F; Iannelli F; Roca MS; Macchini M; Bruzzese F; Garcia Bermejo ML; Rodriguez Garrote M; Tortora G; Milella M; Reni M; Fuchs C; Hewitt E; Kubiak C; Di Gennaro E; Giannarelli D; Avallone A
    BMC Cancer; 2024 Sep; 24(1):1167. PubMed ID: 39300376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase II study.
    Takano N; Yamada S; Hirakawa A; Yokoyama Y; Kawashima H; Maeda O; Okada T; Ohno E; Yamaguchi J; Ishikawa T; Sonohara F; Suenaga M; Takami H; Hayashi M; Niwa Y; Hirooka Y; Ito Y; Naganawa S; Ando Y; Nagino M; Goto H; Fujii T; Kodera Y
    Nagoya J Med Sci; 2019 May; 81(2):233-239. PubMed ID: 31239592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
    Von Hoff DD; Ramanathan RK; Borad MJ; Laheru DA; Smith LS; Wood TE; Korn RL; Desai N; Trieu V; Iglesias JL; Zhang H; Soon-Shiong P; Shi T; Rajeshkumar NV; Maitra A; Hidalgo M
    J Clin Oncol; 2011 Dec; 29(34):4548-54. PubMed ID: 21969517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.